insulin NPH vs SAR341402

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin NPH · Humulin N

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

SAR341402

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT03211858 · Phase 3 · completed

The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.

Reported efficacy

Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)

Result source: NCT03211858

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin NPHSAR341402
HbA1c, change—Not posted · NCT00604396-0.4% vs -0.3%vs NovoLog/NovoRapidwk 26 · n 301NCT03211858
1 other result
  • -0.3% vs -0.3% wk 52 · n 301 · Phase 3 · secondary NCT03211858
Body weight, change (kg)12.6 vs 13vs Levemirn 42NCT01837680—Not reported
HbA1c below 7%—Not posted · NCT0060439619.6% vs 18.2%vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • 16.6% vs 14.5% wk 26 · n 301 · Phase 3 · secondary NCT03211858
Fasting plasma glucose, change—Not posted · NCT00604396-0.1 vs -0.3vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • -0.5 vs -0.2 wk 26 · n 301 · Phase 3 · secondary NCT03211858
3-point MACE (% with event)—Not posted · NCT00604396—Not reported

HbA1c, change

insulin NPH
—Not posted · NCT00604396
SAR341402
-0.4% vs -0.3%vs NovoLog/NovoRapidwk 26 · n 301NCT03211858
1 other result
  • -0.3% vs -0.3% wk 52 · n 301 · Phase 3 · secondary NCT03211858

Body weight, change (kg)

insulin NPH
12.6 vs 13vs Levemirn 42NCT01837680
SAR341402
—Not reported

HbA1c below 7%

insulin NPH
—Not posted · NCT00604396
SAR341402
19.6% vs 18.2%vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • 16.6% vs 14.5% wk 26 · n 301 · Phase 3 · secondary NCT03211858

Fasting plasma glucose, change

insulin NPH
—Not posted · NCT00604396
SAR341402
-0.1 vs -0.3vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • -0.5 vs -0.2 wk 26 · n 301 · Phase 3 · secondary NCT03211858

3-point MACE (% with event)

insulin NPH
—Not posted · NCT00604396
SAR341402
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. insulin NPH: 3 of 4 rows · SAR341402: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin NPHSAR341402
Dropout rate
19.2%a
NCT01837680 · Phase na · registry result, not featured evidence
12.3%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Discontinued due to AEs
—a
NCT01837680 · Phase na · registry result, not featured evidence
2.7%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Serious AEs
0%a
NCT01837680 · Phase na · registry result, not featured evidence
12%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Most frequent reported AEs
a
biochemical event of hypoglycemia 26.9%
symptomatic hypoglycemia 21.2%
rash 11.5%
NCT01837680 · Phase na · registry result, not featured evidence
nasopharyngitis 11.3%
upper respiratory tract infection 7.3%
influenza 5%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin NPH

Glucose mg/dL 6.08 vs 5.96 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 109.5 mg/dL as posted
Glucose Target Attainment 66.7% (n=42) vs 77.8% (n=45) Levemir
event count · % of participants
NCT01837680 · Phase na · registry result, not featured evidence · converted to % from 28 Participants as posted
Time to Glycemic Control 1.15 vs 1.15 Levemir months
time to event · months
NCT01837680 · Phase na · registry result, not featured evidence · converted to months from 5 weeks as posted
Fasting Plasma Glucose mg/dL 5.59 vs 5.4 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 100.7 mg/dL as posted
Postprandial Plasma Glucose mg/dL 6.39 vs 6.27 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 115.2 mg/dL as posted
Weight 12.6 vs 13 Levemir kg
absolute change · kg
NCT01837680 · Phase na · registry result, not featured evidence · converted to kg from 27.7 lbs as posted
Birth Weight Grams 3230 vs 3235 Levemir g
absolute value · g
NCT01837680 · Phase na · registry result, not featured evidence

SAR341402

HbA1c -0.38% (n=301) vs -0.3% (n=296) NovoLog/NovoRapid @ 26wk
absolute change · percentage points
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
-0.25% (n=301) vs -0.26% (n=296) NovoLog/NovoRapid @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
HbA1c Less Than 7% 16.6% (n=301) vs 14.5% (n=296) NovoLog/NovoRapid @ 26wk
responder rate · % of participants
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
19.6% (n=301) vs 18.2% (n=296) NovoLog/NovoRapid @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.49 vs -0.17 NovoLog/NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
-0.1 vs -0.34 NovoLog/NovoRapid mmol/L @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Daily Plasma Glucose -0.34 vs -0.53 NovoLog/NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
0.12 vs -0.18 NovoLog/NovoRapid mmol/L @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin NPH's landscape · SAR341402's landscape